johimban-16-karboksilat

| image = Rescinnamine.svg
| width = 300
| image2 =
| width2 =

| tradename = 
| pregnancy\_category = 
| legal\_status = Rx-only
| routes\_of\_administration = oralno

| bioavailability = 
| protein\_bound = 
| metabolism = 
| elimination\_half-life =

| CASNo\_Ref = DaY
| CAS\_number\_Ref = DaY
| CAS\_number = 24815-24-5
| ATC\_prefix = C02
| ATC\_suffix = AA01
| ATC\_supplemental = 
| PubChem = 5280954
| IUPHAR\_ligand =
| DrugBank\_Ref = Šablon:Drugbankcite

```
| DrugBank = DB01180
```

| ChemSpiderID\_Ref = DaY
| ChemSpiderID = 4444446
| UNII\_Ref = DaY
| UNII = Q6W1F7DJ2D
| KEGG\_Ref = DaY
| KEGG = D00198
| ChEBI\_Ref = DaY
| ChEBI = 28572
| ChEMBL\_Ref = DaY
| ChEMBL = 1668

| C=35 | H=42 | N=2 | O=9 
| molecular\_weight = 634,716 g/mol
| smiles = O=C(OC)[C@H]6[C@H]4C[C@@H]3c2nc1cc(OC)ccc1c2CCN3C[C@H]4C[C@@H](OC(=O)\C=C\c5cc(OC)c(OC)c(OC)c5)[C@@H]6OC
| InChI = 1/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
| InChIKey = SZLZWPPUNLXJEA-QEGASFHIBN
| StdInChI\_Ref = DaY
| StdInChI = 1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
| StdInChIKey\_Ref = DaY
| StdInChIKey = SZLZWPPUNLXJEA-QEGASFHISA-N
| synonyms = metil (1*R*,15*S*,17*R*,18*R*,19*S*,20*S*)-6,18-dimetoksi-17[(2*E*)-3-(3,4,5-trimetoksifenil)prop-2-enoil]oksi3,13-diazapentaciklo[11.8.0.02,10.04,9.015,20]henikosa-2(10),4(9),5,7-tetraen-19-karboksilat
}}
**Rescinnamin** je Inhibitor angiotenzin konvertujućeg enzima koji se koristi kao antihipertenziv.

On je vinka alkaloid koji se dobija iz biljke *Rauwolfia serpentina* i drugih *Rauwolfia* vrsta.

On je dostupan pod trgovačkim imenima: *Moderil*, *Cinnasil*, *Anaprel*.

Spoljašnje veze
---------------


|  |  |
| --- | --- |
|  | ***Portal Medicina***  |
|  | ***Portal Hemija***  |
|

  


| * p
* r
* u
Simpatolitički (i blisko srodni) antihipertenzivi (C02) |
| --- |
| Simpatolitici(antagoniziraju α-adrenergičkuvazokonstrikciju) | 

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Centralni | 

|  |  |
| --- | --- |
| α2 agonist | Klonidin \* Gvanfacin \* Metildopa # |
| Inhibitori otpuštanja adrenalina | Betanidin \* Bretilijum \* Debrisokvin \* Gvanadrel \* Gvanazodin \* Gvanetidin \* Gvanoklor \* Gvanoksan \* Gvanoksabenz |
| Agonist imidazolinskog receptora | Moksonidin \* Rilmenidin |
| Ganglion blokirajući/nikotinski antagonist | Mekamilamin \* Pentolinijum \* Trimetafan |

 |
| Periferalni | 

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Indirektni | 

|  |  |
| --- | --- |
| MAOI | Pargilin |
| Inhibitor adrenergičkog preuzimanja | Bietaserpin \* Deserpidin \* Metoserpidin \* Rescinamin \* Reserpin |
| Inhibitor tirozinske hidroksilaze | Metirozin |

 |
| Direktni | 

|  |  |
| --- | --- |
| α1 blokatori | Prazosin \* Indoramin \* Trimazosin \* Doksazosin \* Urapidil |
| Neselektivni α blokator | Fentolamin |

 |

 |

 |
| Drugi antagonisti | 

|  |  |
| --- | --- |
| Serotoninski antagonist | Ketanserin \* Lidanserin |
| Endotelinski antagonist (za PH) | *dualni* (Bosentan) \* *selektivni* (Ambrisentan, Sitaksentan) |

 |
| #WHO-EM. ‡Povučeni sa tržišta. Kliničko ispitivanje: †Faza III. §Nikad do faze III

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 

|  |  |  |  |
| --- | --- | --- | --- |
| 
M: VAS
 | 
anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
 | 
vabo/siva/kong/tumr, sizn/epon
 | 
proc, lek (C2s+n/3/4/5/7/8/9)
 |

 |

 |